SpectrumDNA Competitors
| SPXA Stock | USD 0.01 0.00 0.00% |
SpectrumDNA vs Ilustrato Pictures Correlation
As of February 3, 2026, Return On Tangible Assets is expected to decline to -4.45. The current year's Return On Capital Employed is expected to grow to -5.48. At present, SpectrumDNA's Total Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 583.7 K, whereas Other Assets are forecasted to decline to about 117 K.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of SpectrumDNA's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
SpectrumDNA Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between SpectrumDNA and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of SpectrumDNA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of SpectrumDNA does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between SpectrumDNA Stock performing well and SpectrumDNA Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze SpectrumDNA's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MDCE | 10.37 | 1.26 | 0.05 | 0.37 | 10.91 | 33.33 | 106.67 | |||
| TMOL | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| HAON | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| WHLT | 16.71 | 6.43 | 0.00 | 1.46 | 0.00 | 27.31 | 370.83 | |||
| GRNL | 22.25 | 2.71 | 0.12 | 0.68 | 20.28 | 50.00 | 255.81 | |||
| CSOL | 7.82 | 1.51 | 0.04 | (6.27) | 11.39 | 24.14 | 120.03 | |||
| VAYK | 8.55 | 0.09 | 0.00 | 0.01 | 0.00 | 25.00 | 62.86 | |||
| GRLF | 7,458 | 4,011 | 87.40 | (0.78) | 0.00 | 100.00 | 249,986 | |||
| ATYG | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| ILUS | 8.47 | (0.06) | 0.01 | 0.04 | 12.70 | 33.33 | 100.00 |
Cross Equities Net Income Analysis
Compare SpectrumDNA and related stocks such as Medical Care Technologies, Trimol Group, and Halitron Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TMOL | 476 K | (785 K) | (638 K) | (217 K) | (182 K) | (182 K) | (182 K) | (182 K) | (182 K) | (182 K) | (182 K) | (182 K) | (182 K) | (182 K) | (182 K) | (163.8 K) | (155.6 K) |
SpectrumDNA and related stocks such as Medical Care Technologies, Trimol Group, and Halitron Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in SpectrumDNA financial statement analysis. It represents the amount of money remaining after all of SpectrumDNA operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.SpectrumDNA Competitive Analysis
The better you understand SpectrumDNA competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, SpectrumDNA's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across SpectrumDNA's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
SpectrumDNA Competition Performance Charts
Five steps to successful analysis of SpectrumDNA Competition
SpectrumDNA's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by SpectrumDNA in relation to its competition. SpectrumDNA's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of SpectrumDNA in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact SpectrumDNA's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to SpectrumDNA, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your SpectrumDNA position
In addition to having SpectrumDNA in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Farming Thematic Idea Now
Farming
Companies producing farming products and providing services for farmers. The Farming theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Farming Theme or any other thematic opportunities.
| View All Next | Launch |
Check out SpectrumDNA Correlation with its peers. For information on how to trade SpectrumDNA Stock refer to our How to Trade SpectrumDNA Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Software - Application space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SpectrumDNA. If investors know SpectrumDNA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive SpectrumDNA assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of SpectrumDNA is measured differently than its book value, which is the value of SpectrumDNA that is recorded on the company's balance sheet. Investors also form their own opinion of SpectrumDNA's value that differs from its market value or its book value, called intrinsic value, which is SpectrumDNA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SpectrumDNA's market value can be influenced by many factors that don't directly affect SpectrumDNA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SpectrumDNA's value and its price as these two are different measures arrived at by different means. Investors typically determine if SpectrumDNA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, SpectrumDNA's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.